Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
8.02
-0.10 (-1.23%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Evolus Revenue
Evolus had revenue of $84.08M in the quarter ending June 30, 2026, with 21.18% growth. This brings the company's revenue in the last twelve months to $316.49M, up 13.87% year-over-year. In the year 2025, Evolus had annual revenue of $297.18M with 11.61% growth.
Revenue (ttm)
$316.49M
Revenue Growth
+13.87%
P/S Ratio
1.67
Revenue / Employee
$896,567
Employees
353
Market Cap
529.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 297.18M | 30.90M | 11.61% |
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | 34.93M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 915.45M |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 808.21M |
| Amphastar Pharmaceuticals | 730.02M |
| Ironwood Pharmaceuticals | 389.32M |
| Canopy Growth | 206.77M |
| Kamada | 181.68M |
| Glass House Brands | 177.68M |
EOLS News
- 8 days ago - Evolus reports Q2 EPS (12c), consensus (4c) - TheFly
- 8 days ago - Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M - TheFly
- 8 days ago - Evolus Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Evolus Earnings release: Q2 2026 - Filings
- 8 days ago - Evolus Slides: Q2 2026 - Filings
- 8 days ago - Evolus Quarterly report: Q2 2026 - Filings
- 8 days ago - Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook - Business Wire
- 9 days ago - Evolus expands strategic partnership with Symatese to commercialize Estyme - TheFly